 |
|
Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab
Florent Grange, MD, PhD;
Eve Maubec, MD;
Martine Bagot, MD, PhD;
Marie Beylot-Barry, MD, PhD;
Pascal Joly, MD, PhD;
Stéphane Dalle, MD;
Emmanuel Delaporte, MD;
Olivier Dereure, MD, PhD;
Hervé Bachelez, MD, PhD;
Béatrice Vergier, MD, PhD;
Tony Petrella, MD;
Michel D’Incan, MD, PhD
Arch Dermatol. 2009;145(3):329-330.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In contrast with most primary cutaneous B-cell lymphomas, primary cutaneous large B-cell lymphomas, leg type (PCLBCLs-LT) are often life-threatening.1-3 Owing to their occurrence in elderly patients (many patients aged >80 years), these lymphomas have often been treated with radiotherapy alone or palliative chemotherapies, resulting in 5-year survival rates around 50%.1-3 Recently, the addition of rituximab to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) (R-CHOP) was found to prolong survival in 60- to 80-year-old patients with nodal diffuse large B-cell lymphomas (DLBCLs).4-5 Although this result was not directly applicable to older patients with PCLBCL-LT, it rapidly led to a significant shift in French practice, consisting . . . [Full Text of this Article]Methods
Results
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cutaneous Lymphomas: What Can We Learn From Location?
Grange and Antonicelli
Arch Dermatol 2009;145:710-712.
FULL TEXT
|
